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Abstract
Background: Prostate cancer (PrCa) displays resistance to radiotherapy (RT) and requires radiotherapy dose
escalation which is associated with greater toxicity. This highlights a need to develop radiation sensitizers to
improve the efficacy of RT in PrCa. Ionizing radiation (IR) stimulates pathways of IR-resistance and survival mediated
by the protein kinase Akt but it also activates the metabolic energy sensor and tumor suppressor AMP-Activated
Protein Kinase (AMPK). Here, we examined the effects of the polyphenol resveratrol (RSV) on the IR-induced
inhibition of cell survival, modulation of cell cycle and molecular responses in PrCa cells.
Methods: Androgen-insensitive (PC3), sensitive (22RV1) PrCa and PNT1A normal prostate epithelial cells were
treated with RSV alone (2.5-10 μM) or in combination with IR (2-8 Gy). Clonogenic assays, cell cycle analysis,
microscopy and immunoblotting were performed to assess survival, cell cycle progression and molecular
responses.
Results: RSV (2.5-5 μM) inhibited clonogenic survival of PC3 and 22RV1 cells but not of normal prostate PNT1A
cells. RSV specifically sensitized PrCa cells to IR, induced cell cycle arrest at G1-S phase and enhanced IR-induced
nuclear aberrations and apoptosis. RSV enhanced IR-induced expression of DNA damage (gH2Ax) and apoptosis
(cleaved-caspase 3) markers as well as of the cell cycle regulators p53, p21cip1 and p27kip1. RSV enhanced IR-
activation of ATM and AMPK but inhibited basal and IR-induced phosphorylation of Akt.
Conclusions: Our results suggest that RSV arrests cell cycle, promotes apoptosis and sensitizes PrCa cells to IR
likely through a desirable dual action to activate the ATM-AMPK-p53-p21cip1/p27kip1 and inhibit the Akt signalling
pathways.
Keywords: radio-sensitizers, clonogenic survival, cell cycle, ATM, p53, p21cip1
Introduction
Radiotherapy is an effective therapy for localized pros-
tate cancer (PrCa) but this disease is highly resistant to
ionizing radiation (IR). Conventional radiotherapy doses
up to 70 Gy show biochemical failure rates of 30% or
more in localized disease [1], leading to a need for RT
dose escalation, which is associated with rectal and blad-
der toxicity. Therefore, there is a need for rational
development of effective radiosensitizers for PrCa.
The phosphatidylinositol 3-kinase (PI3k)-Protein
kinase B/Akt (henceforth: Akt) pathway is known to
promote proliferation, cell cycle progression and resis-
tance to cytotoxic therapies in PrCa [2]. PI3k is an effec-
tor of the epidermal growth factor receptor (EGFR) [3],
that leads to recruitment of Akt and its activators to
plasma membrane. Akt is activated by phosphorylation
on residues T308 and serine S473, both of which are
required for activation [4]. T308 phosphorylation is
mediated by the phosphoinoisitide-dependent kinase 1
(PDK1) [5] but the kinase mediating S473 phosphoryla-
tion (PDK2) is not clearly defined. Candidate kinases
include the DNA damage sensor Ataxia Telangiectasia
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Mutated (ATM) [6]. Activated Akt mediates transcrip-
tion of genes involved in survival and inhibition of those
involved in apoptosis (see [2,7] for review). It promotes
cell cycle progression through inhibition of the cell cycle
regulators p53 [8] and the cyclin-dependent kinase inhi-
bitors (CDKI) p21cip1 and p27kip1 [9,10]. Furthermore, it
regulates metabolic and nuclear processes through acti-
vation of the mammalian target-of-rapamycin (mTOR).
Importantly, IR elicits cytoprotective responses mediated
in part through activation of the PI3k-Akt pathway [11].
Akt is a mediator of radioresistance and PI3k-Akt path-
way inhibitors are shown to enhance radiosensitivity of
cancer cells [7,12].
AMPK is a heterotrimeric enzyme that consists of an
a-catalytic and b-and g-regulatory subunits [13]. It is a
key regulator of carbohydrate and lipid metabolism and
of proliferation in normal and cancer cells. AMPK
detects an elevated AMP/ATP ratio in conditions of
metabolic stress such as starvation and exercise [13] and
promotes energy conservation by inhibiting protein
synthesis, through mTOR inhibition while it also func-
tions as a metabolic checkpoint to induce cell cycle
arrest via p53 [14]. Recently, we showed that IR acti-
vates AMPK in human lung, breast and PrCa cells and
suggested that AMPK participates in a signaling pathway
involving ATM-AMPK-p53-p21cip1 leading to regulation
of the cell cycle and survival [15].
RSV (3,4’,5-trihydroxystilbene) is a polyphenolic phy-
toalexin with widely reported anti-aging and anti-cancer
properties [16,17]. It inhibits cancer cell proliferation
and is suggested to enhance radiation responses [18,19].
RSV has also been reported to increase metabolic rate
and reduce fat mass in wild-type mice but not in AMPK
a subunit knockout mice [20]. Further, it was shown to
suppress tumor growth and metastasis in the mouse
Lewis lung carcinoma model [21]. RSV is known to reg-
ulate both Akt and AMPK [22,23] but the effects of this
compound on the two signaling pathways have not been
studied in radiated cells.
Here, we investigated the polyphenol RSV due to the
reported ability of this natural compound to modulate
both the radioresistance-mediating Akt and the tumour
suppressor AMPK pathways [24,25].
Materials and methods
Cell Lines and Cell Culture
Human PrCa (PC3, 22RV1) and normal prostate epithe-
lial (PNT1A) cell lines were obtained from American
Tissue Culture Collection (Manassas, VA, U.S.A.). Cells
were maintained at 37°C in RPMI media supplemented
with 10% (vol/vol) Fetal Bovine Serum (FBS) and 1%
(vol/vol) antibiotic-antimycotic (Invitrogen, Burlington,
ON, Canada).
Reagents and Antibodies
Rabbit polyclonal antibodies against total Akt (T-Akt),
phosphorylated-(P)-(S473)-Akt, P-(T308)-Akt, P-mTOR,
total AMPK (T-AMPK), P-(Thr172)-AMPK, T-ATM, P-
(S1981)-ATM, P-(S139)-gH2Ax, mouse monoclonal
antibodies against p53, p21cip1, p27kip1, actin, an anti-a-
tubulin antibody conjugated to Alexa Fluor 488 as well
as horseradish peroxidase (HRP)-conjugated IgG sec-
ondary anti-rabbit and anti-mouse antibodies were from
New England Biolabs (Mississauga, ON, Canada).
Hoechst 33258 was from Sigma (Toronto, ON, Canada).
RSV and the KuDos Pharma ATM inhibitor KU55933
were from Calbiochem (Mississauga, ON, Canada).
Anti-a1 and -a2 AMPK siRNA transfection kit was
obtained from Qiagen (Mississauga, Ontario, Canada).
Treatments
Cells were treated with 2-8 Gy IR using a 60Co clinical
unit. For combined RSV or KU55933 and IR treatments,
cells were kept at 37°C with the indicated agent for 1 h
prior to IR treatment. Cells were incubated for 1 h fol-
lowing IR exposure, unless otherwise indicated. For cell
cycle and clonogenic assays cells were exposed to the
treatment agents throughout the experiments (as indi-
cated in figure legends).
siRNA AMPK a Subunit Knockdown
Cells were incubated with a mixture of human siRNA
sequences against the a1 and a2 AMPK subunits using
HiPerFect vehicle for 72 hours as per the manufacturer’s
protocol.
Clonogenic Assays
Clonogenic assays were performed as described earlier
[15]. Cells (500-1000) were seeded in triplicates and
allowed to adhere overnight, then were incubated with
RSV followed by IR treatment (0-2 Gy) followed by
incubation for 7-10 days. Cells were then fixed and
stained with 0.05% methylene blue and colonies (> 50
cells) were counted. Results are expressed as the surviv-
ing fraction compared to untreated control.
Immunoblotting (IB)
IB was performed as described earlier [26]. Approxi-
mately 5 × 105 cells were seeded in 6-well plates. After
treatment, cells were washed, lysed and twenty micro-
grams of protein were subjected to IB.
Immunofluorescence Microscopy
Cells (2 × 105) were seeded onto glass coverslips and
were incubated without or with RSV (5 μM) 1 h prior
to IR treatment (8 Gy). Ninety six hours after IR expo-
sure, cells were washed lightly with PBS and fixed with
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3% paraformaldehyde/PBS/0.2% Triton X-100 for 20
minutes. Cells were stained with Hoechst 33258 (20
μM) nuclear stain or anti-a-tubulin antibody conjugated
to Alexa Fluor 488 (1:100 dilution) (followed by Hoechst
33258 nuclear staining) and examined by fluorescence
microscopy. Four hundred cells were evaluated for
nuclear aberrations (fragmentation, micro-nuclei and
multi-nucleation) in four representative areas of each
slide in 3 independent experiments.
Cell Cycle Analysis
(1 × 106 cells/mL) were seeded in 10-cm dishes. After
treatment, cells were trypsinized, washed, fixed with
70% ethanol and stored overnight at -20°C followed by
washing and staining with a solution containing 100 μL
Triton X-100 and 50 μg/mL propidium iodide. Cells
were subjected to flow cytometric cell cycle analysis
using a Beckman Coulter Epics XL flow cytometer.
Statistical Analysis
Data are expressed as the mean ± standard error (SE).
Statistical analysis was performed using unpaired t-test
with SPSS v16.0 software (SPSS, Chicago, IL). Statistical
significance was considered at p < 0.05.
Results
RSV inhibits PrCa cell survival
As a single agent, RSV effectively inhibited survival of
both PC3 and 22RV1 PrCa cells with significant inhibi-
tion achieved at even the lower doses of 2.5 and 5 μM
(p < 0.05) (Figure 1A). The IC50 values were approxi-
mately 10 μM and 2.5 μM for PC3 and 22RV1 cells,
respectively. The PC3 response to RSV was dose-depen-
dent. RSV 2.5 μM significantly decreased survival in
22RV-1 cells to 40 ± 3.06% of control without any
further decrease at higher doses. In contrast, PNT1A
normal epithelial cells were less responsive to RSV
showing only 5 and 10% inhibition of survival at 2.5 and
5 μM, respectively (Figure 1A). Only the higher dose of
10 μM caused significant decrease in normal epithelial
PNT1A cell survival (to 60 ± 12.26% of control) (p <
0.05). PTN1A cells were used here as a non-malignant
control.
IR-induced inhibition of PrCa cell survival
PC3 cells showed greater resistance to IR alone com-
pared to 22RV1 cells (surviving fractions after 2 Gy
(SF2) of 60 ± 5.30% vs 40 ± 3.53%, respectively, Figure
1B). Their IR sensitivity was similar to that of PNT1A
cells (SF2 of 62.9 ± 2.26%, Figure 1B). In clonogenic
assays we opted to use the standard therapeutic IR dose
of 2 Gy and not high doses of IR, for clinical relevance
and because higher doses (i.e. 6-8 Gy) were highly toxic
to PrCa cells in agreement with previous reports [27].
RSV enhances the IR-induced inhibition of clonogenic
survival in PrCa cells
RSV augmented further the IR-induced inhibition of
survival in both PC3 and 22RV1 PrCa cells. RSV (2.5
and 5 μM) decreased survival of IR-treated PC3 cells by
(13.8 ± 0.09% and 20.4 ± 0.9%, Figure 1B). RSV 5 μM
caused only a minor reduction of SF2 in 22RV1 cells
(non-significant) but at 10 μM the drug induced a sig-
nificant 2.5-fold inhibition in SF2. RSV (5 μM) pre-treat-
ment did not decrease further SF2 of PNT1A prostate
epithelial cells but this was achieved when RSV was
increased to 10 μM (Figure 1B).
To better demonstrate the potential clinical benefit
of RSV in combination with radiotherapy, we used SF2
values to estimate tumour cell survival after 40 frac-
tions of radiotherapy (2 Gy each), which consists a
standard approach in clinical PrCa management [1].
We determined (SF2)n as the tumour cell fraction sur-
viving after “n” fractions of radiotherapy. Assuming
iso-effectiveness of all fractions, we plotted the pro-
jected tumour survival over 40 consecutive fractions
(0-80 Gy) (Figure 1C). As typical human prostates
range between 35-100 gr (5 - 10 × 1010 cells) we
plotted projected tumour size reductions (tumour kill-
ing) on a scale of 1 - 1 × 10-11. Figure 1C estimates
that RSV (5 μM) may be able to reduce the dose of
radiotherapy needed to eliminate 22RV1 type (hor-
mone-sensitive) PrCa tumours (from about 47 to 40
Gy) and may be able to eliminate PC3 type (hormone-
insensitive) PrCa tumours (with about 54 Gy) that
would otherwise be incurable with doses even higher
than 80 Gy. Further, this approach also demonstrated
the complete lack of radio-sensitization of normal
epithelial cells (PNT1A) by 5 μM RSV. Based on these
results, we pursued all subsequent studies with PrCa
cells alone and with doses of 2.5 - 5 μM RSV.
RSV inhibits IR-mediated cell cycle arrest and induces cell
accumulation at G1-S and sub-G1 phases consistent with
apoptosis
We utilized the 22RV1 cell line in our cell cycle analy-
sis experiments because it is a cloned cell line [28]
consisting of a more isogenic population of cells than
PC3 cells, and is hence appropriate for cell cycle analy-
sis. As expected, IR induced an arrest of cells at the
G2-M interphase (Control: 13.4% vs. IR: 31.7%, Figure
2) but pre-treatment with RSV (5 μM) prevented this
event (RSV+IR: 8.3% vs. 31.7% for IR, Figure 2). RSV
caused accumulation of radiated cells into the G1-S
phases of the cycle (IR: 58% vs. RSV + IR: 70.7%) and
increased the population of cells in the sub-G1 region
by 2-fold compared to those treated with IR alone (IR:
10.3% vs. RSV + IR: 21.0%), indicating induction of
apoptosis.
Rashid et al. Radiation Oncology 2011, 6:144
http://www.ro-journal.com/content/6/1/144
Page 3 of 12
RSV enhances the IR induction of cell cycle inhibitors
To examine whether the effects of RSV on IR regulation
of the cell cycle were associated with enhancement of
molecular pathways of cell cycle regulation, we exam-
ined the expression of p53 and the cyclin-dependent
kinase inhibitors (CDKI) p21cip1 and p27kip1. Figure 2B
shows that IR induced expression of both p53 and the
CDKIs in 22RV1 cells and that RSV enhanced this
further. Similar results were obtained for the two CDKIs
in p53-null PC3 cells.
RSV induces expression of apoptotic markers and nuclear
aberrations
Using immunoblotting with a cleaved caspase-3-specific
antibody, we examined the effects of RSV and IR on the
levels of this established apoptosis marker. IR increased
caspase-3 cleavage within 1 hour of IR exposure in both
PC3 and 22RV1 cells (Figure 3A). Pre-treatment with
RSV (2.5 and 5 μM) enhanced the IR-induced cleaved
caspase-3 levels in a dose-dependent fashion.
To evaluate morphological markers of apoptosis, cells
were stained with Hoechst 33258 and examined with
microscopy. Cells with nuclear aberrations such as frag-
mentation, micro-nuclei and multi-nucleation (polys-
omy), which are markers predictive of apoptosis and/or
mitotic cell death (mitotic catastrophe), were counted in
each treatment condition. Figure 3B shows representa-
tive images of treated PC3 cells that were either stained
with Hoechst 33258 alone (low magnification, Figure
3B) or additional immunostaining of tubulin (high
Figure 1 Effects of resveratrol (RSV) and ionizing radiation (IR) on survival of prostate cancer (PrCa) cells. A. Cells were incubated with
increasing doses of RSV (0-10 μM) and allowed to form colonies. Colonies (> 50 cells) were counted. Results are expressed as the surviving fraction
compared to untreated control (see Methods). ‘*’ p < 0.05 compared to untreated PC3 cells, ‘#’ p < 0.05 compared to untreated 22RV1 cells, ‘+’ p <
0.05 compared to untreated PNT1A cells. B. Cells were pre-treated with RSV (0-10 μM) followed by treatment with a single fraction of IR (2 Gy) and
allowed to grow and form colonies. Treatment values were normalized to untreated controls and surviving fractions are presented as percent of
control. Shown is the mean of 4-5 independent experiments ± standard error (SE). ‘*’ p < 0.05 compared to 2 Gy treated PC3 cells, ‘#’ p < 0.05
compared to 2 Gy treated 22RV1 cells, ‘+’ p < 0.05 compared to 2 Gy treated PNT1A cells. C. Projected proportion of tumour survival after
treatment with 0 - 80 Gy was estimated using the Surviving Fraction at 2 Gy (SF2) values for control and RSV (5 μM) treated PNT1A, PC3 and 22RV1
cells. SF2n was determined as the tumour proportion surviving after “n” 2 Gy fractions, assuming iso-effectiveness of each fraction. Values were
plotted up to a scale of 1 × 10-11 to reflect elimination of tumour of 50 - 100 gr expected to contain 5 - 10 × 1010 cells.
Rashid et al. Radiation Oncology 2011, 6:144
http://www.ro-journal.com/content/6/1/144
Page 4 of 12
magnification), which was utilized to better demonstrate
the effects of the treatments on nuclear and cellular
morphology (Figure 3C). The results of four indepen-
dent experiments (as in Figure 3B) were quantitated (as
described in Methods) and are shown in Figure 3D). IR
alone induced significant nuclear aberrations (43 ±
2.18%, Figure 3B), while RSV alone (5 μM) increased
nuclear abnormalities by 6% (Figure 3B). However, RSV
significantly enhanced the IR-induced nuclear aberra-
tions to 70 ± 3.11% (an increase of 27%, Figure 3D) of
total cell counts and reduced overall cellular viability
(Figure 3B).
Effects of RSV on molecular pathways of radio-resistance
and tumour suppression
RSV inhibits basal and IR-induced levels of phosphorylated
Akt
We examined the effects of RSV on the well-described
radio-resistance pathway of Akt-mTOR. We observed
that IR alone induced a significant time-dependent
Figure 2 Effects of resveratrol (RSV) and ionizing radiation (IR) on prostate cancer cell cycle progression and expression of cycle
regulators. A. 22RV1 cells were pre-treated or not with RSV (5 μM) for 1 hour followed by treatment with 8 Gy IR. Cells were allowed to cycle
for 48 hours after which they were fixed, treated with a triton-X and stained with propidium iodide (PI) solution as described in Methods. Shown
are representative results of 3 independent experiments. Pie charts illustrate the proportion of cells in each phase of cell cycle. B. 22RV1 and PC3
cells were pre-treated with RSV (5 μM) for 1 hour followed by 8 Gy IR treatment. Cells were lysed 1 hour after IR exposure and subjected to
immunoblot analysis using antibodies against the indicated cell cycle markers. Shown are representative immunoblots of 3 independent
experiments.
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increase in the levels of phosphorylated Akt (P-Akt)
(both S473 and T308 sites) in PC3 cells, with no effects
on total levels of the protein (Figure 4A). Highest levels
of P-Akt were reached 30 minutes to 1 hour after IR
exposure. Akt phosphorylation was associated with
increased activity of this enzyme indicated by the IR-
induced phosphorylation of mTOR, a key effector of
Akt (Figure 4A). Similar results were obtained in 22RV1
PrCa cells (results not shown).
Treatment of PC3 and 22RV1 cells with RSV inhibited
basal levels of P-Akt (Figure 4B). Of note, the images
shown were obtained after significantly longer film
exposure to allow demonstration of the effects of RSV
on basal Akt phosphorylation which are significantly
lower than in radiated cells (as shown in Figure 4A and
4C). Pre-treatment with RSV led to significant inhibition
of IR-induced P-Akt with no effects on total levels of
the protein (Figure 4C). Although IR exposure led to an
increase in P-Akt, RSV pre-treatment (2.5 and 5 μM)
significantly reduced and/or prevented IR-induced phos-
phorylation of Akt. The effects of RSV on IR-induced
Akt phosphorylation on S473 were quantitated in four
independent experiments (Figure 4D). Similar results
were obtained for Akt T308 phosphorylation. A
Figure 3 Resveratrol (RSV) enhances ionizing radiation (IR)-induced cell death. Induction of cleaved caspase-3 and nuclear aberrations. A.
PC3 cells were pre-treated or not with RSV (5 μM) for 1 hour after which they were treated with IR (8 Gy). Cells were lysed 1 hour after IR
exposure and subjected to immunoblot analysis using the indicated antibodies. Shown are representative immunoblots of 3-4 independent
experiments. B. and C. Cells were treated or not with RSV (5 μM) prior to IR treatment (8 Gy) followed by staining with nuclear stain Hoeschst
33258 (low magnification, in B) or Hoeschst 33258 and immunostaining of tubulin (high magnification, in C) used to illustrate better cellular
morphology. Morphology was assessed using fluorescence microscopy. Representative images from 4 independent experiments are shown. D.
Average ± SE values (% Nuclear Aberrations: as indicated by the proportion of cells with features of nuclear fragmentation, micro-nuclei and
multi-nucleation) were extracted through quantitation of 4 independent experiments (in B), as described in Methods.
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representative immunoblot from PC3 cells is shown
(Figure 4C).
RSV and IR effects on AMPK
We reported earlier that IR activates AMPK in lung,
breast and prostate cancer cells [15]. Similarly, we
observed here that IR induced a robust phosphorylation
of AMPK on Thr172 of the catalytic a subunit that was
detectable within 15 min. Highest levels of phosphory-
lated AMPK (P-AMPK) were detected 1 hour after IR
exposure and returned to almost basal levels 4 hours
after radiation (Figure 5A). This was associated with
activation of AMPK indicated by the detected phosphor-
ylation of the AMPK substrate Acetyl CoA Carboxylase
(ACC). RSV induced a robust activation of AMPK in
both PC3 and 22RV1 cells at both 2.5 and 5 μM (Figure
5B). Furthermore, RSV pre-treatment enhanced signifi-
cantly the IR-induced AMPK phosphorylation in both
22RV1 and PC3 cells (Figure 5C). Total AMPK levels
remained unchanged after both IR and RSV treatments.
The results of 3-4 independent experiments were quan-
titated and are shown in Figure 5D.
The pathway of radiation activation of Akt and AMPK
Akt regulation
Recent reports suggest that Akt activation by IR may be
regulated by ATM [29]. We examined this notion in
Figure 4 Resveratrol (RSV) inhibits basal and ionizing radiation (IR)-induced Akt phosphorylation. A. Effects of IR alone: PC3 cells were
treated with 0 or 8 Gy IR and lysed according to the indicated time points following IR exposure. Then cells were subjected to immunoblot
analysis. B. RSV inhibits basal Akt phosphorylation: PC3 and 22RV-1 cells were treated with RSV (0, 2.5 or 5 μM) for 1 hour and subjected to lysis
and immunoblot analysis using the indicated antibodies. C. RSV inhibits IR-induced Akt phosphorylation. PC3 and 22RV-1 cells were pre-treated
with the indicated concentrations of RSV 1 hour prior to IR treatment. Cells were lysed 1 hour after IR exposure and subjected to immunoblot
analysis. Shown are representative immunoblots of 4 independent experiments. D. Densitometric quantitation of Akt (S473) phosphorylation and
total Akt was performed. P-Akt was normalized to T-Akt levels and presented as fold change compared to untreated control cells (mean ± SE)
from 3-4 independent immunoblotting experiments as in C). * p < 0.05 compared to cells treated with IR alone.
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PrCa cells using the ATM-specific inhibitor KU55933
[30]. Pre-incubation with KU55933 prevented IR-
induced ATM phosphorylation but also inhibited IR
phosphorylation of Akt at S473 and activation of its
kinase activity as indicated by reduced phosphorylation
of mTOR (Figure 6A).
AMPK Regulation
We attempted to verify, in PrCa cells, our earlier obser-
vations in lung cancer cells [15] of AMPK participation
in an ATM-AMPK-p53/p21cip1 pathway activated by IR.
We observed a robust phosphorylation of ATM and
AMPK as well as induction of p21cip1 in PC3 PrCa cells
in response to IR. IR induced ATM and AMPK phos-
phorylation and p21cip1 induction were all inhibited by
treatment with KU55933 (Figure 6B). To verify that
AMPK truly acts as a mediator of p53/p21cip1 induction
in response to IR in PrCa cells, we used wild-type p53
expressing 22RV1 cells to perform AMPK knockdown
experiments. siRNA knockdown of both a1 and a2
subunits of AMPK blocked p53 and p21cip1 induction by
IR (Figure 6C). Interestingly, RSV pre-treatment
enhanced IR-induced phosphorylation of ATM and of
its substrate histone H2Ax (gH2Ax), as well as phos-
phorylation of AMPK and induction of p21cip1.
Discussion
IR and RSV effects on PrCa cell clonogenic survival
RSV inhibits survival and proliferation of cancer cells as
a single agent and induces radiosensitization in human
cervical cancer cells [19]. Similarly, we observed that at
low doses (2.5-10 μM) RSV inhibited clonogenic survival
of PrCa cells. Several studies have reported IC50 values
for cell growth inhibition by RSV in the range of 5 to
10 μM [31,32]. Free RSV has a low bioavailability in-
vivo as it is rapidly metabolized to glucoronide and sul-
fate conjugates [32]. A human study reported plasma
concentrations of free RSV of 21 nM after oral dose of
25 mg RSV [32]. However, all combined RSV
Figure 5 Resveratrol (RSV) enhances basal and ionizing radiation (IR)-induced AMPK phosphorylation. A. Effects of IR alone: PC3 cells
were treated with 0 or 8 Gy IR and lysed at the indicated time points after IR exposure. The adjacent panel shows PC3 cells treated with 8 Gy
IR, which were lysed 1 hour after IR treatment. Samples were subjected to immunoblot analysis using the indicated antibodies. B. RSV enhances
basal AMPK phosphorylation: PC3 and 22RV-1 cells were treated with the indicated concentrations of RSV for 1 hour followed by lysis and
immunoblotting analysis. C. RSV enhances IR-induced AMPK phosphorylation. PC3 and 22RV-1 cells were pre-treated with the indicated
concentrations of RSV 1 hour prior to 8 Gy IR treatment. Cells were lysed 1 hour after IR exposure and subjected to immunoblotting using
indicated antibodies. Shown are representative immunoblots of at least 3-4 independent experiments. D. Densitometry-based quantitation.
Density values of P-AMPK were normalized to T-AMPK levels and presented as fold change compared to untreated control cells (mean ± SE)
from 2-3 independent experiments in C. is shown. * p < 0.05 compared to cells treated with IR alone.
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Figure 6 Mechanism of Akt and AMPK regulation by resveratrol (RSV) and ionizing radiation (IR). A. and B. Inhibition of ATM blocks IR-
induced activation of the Akt and AMPK signaling pathways: PC3 cells were treated or not with the ATM inhibitor KU55933 (10 μM) for 1 hour
followed by 0 or 8 Gy IR treatment. Cells were lysed 1 hour after IR exposure and subjected to immunoblot analysis using the indicated
antibodies. C. AMPK mediates the IR induction of p53 and p21cip1: 22RV-1 cells were incubated with siRNA complexes against the a1 and a2
subunits of AMPK for 72 hours as described in Methods. Cells were then treated with 0 or 8 Gy IR and lysed 1 hour after IR exposure and
subjected to immunoblot analysis. D. RSV enhances signalling along the ATM-AMPK-p21cip1 pathway: Cells were pre-treated with RSV (5 μM) for
1 hour followed by IR of 8 Gy. Cells were lysed 1 hour after IR exposure and subjected to immunoblot analysis using the indicated antibodies.
Shown are representative immunoblots of at least 3 independent experiments.
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metabolites were reported to reach about 2 μM [16]. For
this, we pursued our studies with low RSV concentra-
tions (2.5 - 10 μM).
As a single agent, RSV inhibited more potently survi-
val of 22RV1 compared to PC3 cells but the response of
22RV1 cells did not display dose-dependence. Overall,
PC3 cells displayed greater resistance to both IR and
RSV alone, consistent with other studies [33]. PC3 cells
are deficient in key tumour suppressors including PTEN
and p53 [34]. Lack of PTEN allows aberrant Akt activa-
tion [35], which in combination with the lack of p53,
may confer such cells a survival advantage and IR- and
RSV-resistance. PNT1A cells were less responsive to
RSV, indicating a potential for this drug to achieve a
positive therapeutic ratio in-vivo. RSV inhibited signifi-
cantly PNT1A cells at 10 μM and for that we focused
our work on 2.5 and 5 μM RSV.
We demonstrated that RSV can sensitize PrCa cells to
IR (Figure 1). Concentrations of RSV (2.5 and 5 μM),
similar to those that can be achieved in human serum,
enhanced the cytotoxicity of a conventional RT fraction
(2 Gy) in PrCa cells without additional toxicity to nor-
mal epithelial cells. The potential clinical utility of our
finding is illustrated in Figure 1C, which suggests that
low RSV doses have the potential to reduce the dose of
radiotherapy required to treat human hormone- and
radiation-sensitive PrCa and may be able to make cur-
able hormone- and radiation-insensitive tumours that
may otherwise be incurable with even modern dose
escalated radiotherapy. This notion needs to be verified
in in-vivo models of human PrCa.
Regulation of cell cycle and apoptosis
RSV is reported to arrest PrCa and other cells at G0-G1
and/or S-phases of the cycle leading to senescence
[36,37] and cause p21cip1-mediated G1-phase arrest and
apoptosis in A431 cells [38]. Consistently, we observed a
significant arrest of radiated PrCa cells at G1-S (Figure
4). RSV’s effects on survival were additive to those of IR
but the two agents mediate different regulation of cell
cycle. Whereas IR induces G1-S and more so G2-M
cycle arrest, RSV prevented the latter (Figure 2), likely
due to induction of an earlier checkpoint (G1-S). The
potentiation of IR-induced expression of p53 and CDK
inhibitors p21cip1 and p27kip1 by RSV (Figure 2B),
known to regulate the G1 and S phase checkpoints, may
provide a molecular pathway of action for RSV’s induc-
tion of the G1-S phase arrest seen in our studies.
RSV also caused re-distribution of cells into the sub-
G1 or apoptotic range that was associated with cleavage
of caspase-3 and induction of extensive nuclear aberra-
tions (Figure 3). Apoptosis appears to be the primary
mode of cell death induced by RSV. Studies demon-
strated such cell death effects in PrCa cells through
activation of caspase-, p53-, or Fas ligand-dependent
pathways [39,40]. In our studies, IR-mediated nuclear
damage showed early signs of mitotic catastrophe and
RSV potentiated such nuclear aberrations (Figure 3C-D).
Mitotic cell death predominates in cells with defects in
cycle checkpoints that prevent cycle arrest and DNA
repair when cells are exposed to genotoxic stress such
as IR [41]. The features of mitotic catastrophe seen in
our studies in PC3 cells (p53-null) after RSV and IR
treatments are consistent with those observed earlier in
other p53-null cancer models [41].
Modulation of the Akt and AMPK pathways
IR and RSV exert opposite effects on Akt. IR mediated
Akt phosphorylation on T308 and S473 and enzymatic
activation indicated by mTOR phosphorylation (Figure
4A). This suggests activation of both PDK1 and PDK2
activity by IR. However, we observed that RSV is an
effective inhibitor of this radioresistance-associated path-
way (Figure 4). Inhibition of IR-induced T308 and S473
phosphorylation by RSV suggests an ability to regulate
both PDK1 and PDK2. The enhancement of IR-induced
cell death by RSV may indeed be mediated through
modulation of Akt and its downstream targets as sug-
gested earlier for uterine cancer [25] and PrCa cells [42].
Using the ATM-specific inhibitor KU55933, [30] we
observed that ATM mediates IR-induced Akt S473 phos-
phorylation and activation, suggesting that ATM may
indeed be the IR responsive PDK2, as suggested earlier [6].
However, despite inhibition of Akt, RSV enhanced ATM
phosphorylation and activation indicated by histone H2Ax
phosphorylation (gH2Ax) (Figure 6D). This points to a
complex regulatory action of RSV to enhance ATM activa-
tion but inhibit its PDK2 action on Akt downstream. This
concept needs to be explored further in future studies.
We aimed to evaluate, in PrCa cells, the DNA damage
responsive ATM-AMPK-p21cip1 pathway we proposed
earlier in lung cancer cells [15] and found that IR
indeed mediates AMPK activation downstream of ATM
(Figure 6B). We observed that AMPK mediates p53 and
p21cip1 induction in response to IR in PrCa cells (Figure
6C). RSV and IR stimulated phosphorylation/activation
of AMPK, in both PC3 and 22RV1 PrCa cells, which
was associated with induction of p21cip1 and p27kip1
(Figure 6D). Although, we did not examine whether the
latter is regulated by AMPK activity, this notion is well
described by other studies [43]. The enhancement of IR-
stimulated ATM activity by RSV provides a framework
for upregulation of the ATM-AMPK-p21cip1 pathway in
RSV-treated cancer cells and a rationale for the
observed inhibition of cell cycle and survival. This
notion is supported by observations that the AMPK
inhibitor compound C inhibits IR-induced cytotoxicity
in PrCa (results not shown).
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Conclusions
Figure 7 illustrates a model of the effects of RSV on the
IR responses of PrCa cells. Low (μM) concentrations of
RSV, that can be achieved in human serum, inhibit
PrCa cell survival and enhance IR-induced cytotoxicity.
RSV enhances IR-induced DNA-damage response sig-
nals (ATM), apoptosis markers (cleaved caspase-3) and
cell cycle inhibitors (p53, p21cip1 and p27kip1). Further, it
arrests cycling at the G1-S phase and enhances IR-
induced nuclear aberrations. RSV exerts a desirable dual
action to inhibit the Akt radioresistance pathway while
enhancing the tumour suppressor AMPK, leading to
potentiation of an ATM-AMPK-p53-p21cip1 /p27kip1 sig-
naling axis. We conclude that RSV is a promising agent
that deserves further investigation as an adjunct to IR in
in-vivo models of PrCa to help elucidate its potential for
clinical use in combination with RT.
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